Elevance Health, Inc. $ELV is HF Advisory Group LLC’s 7th Largest Position

HF Advisory Group LLC increased its position in Elevance Health, Inc. (NYSE:ELV) by 1,797.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 152,705 shares of the company’s stock after purchasing an additional 144,655 shares during the quarter. Elevance Health makes up about 2.0% of HF Advisory Group LLC’s portfolio, making the stock its 7th biggest position. HF Advisory Group LLC’s holdings in Elevance Health were worth $53,531,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Trust Co. of Vermont increased its stake in shares of Elevance Health by 34.3% during the fourth quarter. Trust Co. of Vermont now owns 231 shares of the company’s stock valued at $81,000 after buying an additional 59 shares during the period. Bank Pictet & Cie Europe AG grew its holdings in Elevance Health by 3.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 1,225 shares of the company’s stock worth $429,000 after acquiring an additional 45 shares in the last quarter. McLean Asset Management Corp grew its holdings in Elevance Health by 10.4% during the 4th quarter. McLean Asset Management Corp now owns 648 shares of the company’s stock worth $242,000 after acquiring an additional 61 shares in the last quarter. Uncommon Cents Investing LLC raised its holdings in shares of Elevance Health by 3.6% in the 4th quarter. Uncommon Cents Investing LLC now owns 4,515 shares of the company’s stock valued at $1,583,000 after purchasing an additional 155 shares in the last quarter. Finally, Elser Financial Planning Inc lifted its position in shares of Elevance Health by 4.8% in the 4th quarter. Elser Financial Planning Inc now owns 894 shares of the company’s stock worth $313,000 after purchasing an additional 41 shares during the period. 89.24% of the stock is owned by institutional investors.

Elevance Health Stock Performance

ELV opened at $298.99 on Thursday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market cap of $65.68 billion, a P/E ratio of 11.90, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. The firm’s 50-day moving average price is $317.51 and its 200-day moving average price is $332.32.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the business earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.3%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend was Tuesday, March 10th. Elevance Health’s dividend payout ratio is presently 27.39%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ELV. Robert W. Baird boosted their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Guggenheim cut their price target on Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Truist Financial reduced their price target on Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Morgan Stanley decreased their price objective on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 17th. Finally, Barclays dropped their price objective on Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.